京新药业 20250710 摘要 金鑫药业创新药地达西尼已上市并纳入医保，2025 年上半年销售额突 破 5,000 万元，预计全年达 1.2-1.3 亿元，市场表现良好，进院数量和 单院产量均符合预期，销量逐月爬升，但综合医院销售节奏稍慢于专科 医院。 口服 RPA 是金鑫药业在血脂异常治疗领域的重要研发成果，目前处于临 床一期试验阶段，已完成部分单剂量和多次给药组试验，预计年内完成 一期试验并启动二期，现有数据显示 LC 降幅良好，与动物实验数据预 期一致。 地达西尼目前已覆盖约 470 家医院，上半年新增 270 多家，目标年底 覆盖 700 家。部分医院月均发货量已达 4,000-5,000 盒以上，整体销 售额逐月增长，从 3 月份约 3 万盒到 6 月份超过 13 万盒，全年目标为 18 万至 20 万盒。 失眠治疗领域在中国沉寂近 20 年，市场需求旺盛。地达西尼临床试验 显示安全性良好，疗效覆盖轻症到重症失眠患者，优于仅适用于轻症患 者的新靶点药物，有望推动整个领域发展。 Q&A 金鑫药业在创新药研发方面的主要方向是什么？ 金鑫药业的创新药研发主要集中在两个大方向：精神神经领域和心脑血管领域。 ...

在跨境电商和社媒营销的领域里，效率常常是跨境人们制胜的关键。而RPA（Robotic Process Automation，机器人流程自动化 ）作为能重塑工作流程的工 具，也正深度改变着跨境人的作业模式。 今天我们就从基础定义、跨境应用场景，到免费使用途径——AdsPower RPA的功能，全方位拆解 RPA，助力跨境业务的效率提高。 全称 Robotic Process Automation，意为"机器人流程自动化"。 它是一种软件机器人，通过模拟人类在电脑上的操作（如点击、复制粘贴、读取、填写表格等），来完成重复性强、规则明确的任务。 （一）特点： （二）跨境电商领域的应用场景： （三）在社媒营销中的具体用法： AdsPower 指纹浏览器作为主流的指纹浏览器和多账号环境管理工具之一，具备多项核心优势： （一）账号隔离与防关联管理 全自动工作：自动登录等一系列工作 零失误操作：规则任务不出错 一个流程做好，可快速复制到多个账号/站点/团队 订单处理自动化 客服数据同步与回复 选品与竞品分析 广告投放自动化 仓储与库存预警 批量内容发布自动化 竞品社媒内容监控 数据采集与增长分析 每个账号运行在独立的浏览器 ...

尽管已有研究尝试引入触觉信息提升策略表现，但往往停留在简单拼接或辅助通道的层面，缺乏结构性设计，难以充分发挥视触结合的潜力。 为应对上述挑战，来自 UC 伯克利、北京大学、Sharpa 等机构的研究人员提出 ViTacFormer，一个融合视觉与触觉信息，并引入未来触觉预测机制的统一框架，专 为提升灵巧操控中的精度、稳定性与持续控制能力而设计 。 灵巧操控是机器人实现类人交互的关键能力，尤其在涉及多阶段、细致接触的任务中，对控制精度与响应时机提出了极高要求。尽管视觉驱动的方法近年来快速 发展，但在遮挡、光照变化或复杂接触环境下，单一视觉感知常常失效。 触觉感知为机器人提供了与环境交互的直接反馈，在判断接触状态、施力时机等方面扮演着不可替代的角色。然而，当前大多数方法仅将触觉信息作为静态输入 进行融合，缺乏真正有效的多模态联合建模机制。更为关键的是，现有方法往往只关注当前的触觉状态，忽视了对未来触觉变化的预测。这种短视导致机器人在 连续操作中难以提前准备、策略难以稳定，特别是在需要时序感知和力觉判断的任务中表现不佳。 近日，一个「人形机器人做汉堡」的视频火爆全网！ 这个具备 [主动视觉]、[高精度触觉] 以及 ...

China Healthcare | Asia Pacific Weekly Rx Express 2025.07.04 July 4, 2025 01:46 PM GMT Sino Biopharma obtained approval for recombinant human coagulation factor VIIa N01: The drug is indicated for the treatment of bleeding episodes in congenital hemophilia patients aged 12 and above, with factor VII or IX inhibitors >5 Bethesda units (BU). (Company filing, July 4, 2025) Hengrui obtained approval for an additional indication for JAK1 inhibitor (ivarmacitinib): Ivarmacitinib is China's first domestically-deve ...

Key Takeaways PATH shares surged 36% in 3 months, signaling a rebound, driven by automation market momentum. Strategic ties with Microsoft, Amazon, and Salesforce are boosting PATH's enterprise integration and reach. PATH trades at 4.43X forward P/S, below the 5.82X industry average, suggesting attractive relative valuation.UiPath Inc. (PATH) shares have surged 36% over the past three months, closely trailing the industry’s 40% growth. This rebound suggests a potential turning point after a difficult year ...

Group 1 - The core viewpoint emphasizes the increasing importance of data infrastructure in driving business innovation and ensuring compliance in the context of digital transformation accelerated by AI and cloud technologies [1] - According to Gartner, global public cloud service end-user spending is projected to reach $723.4 billion by 2025, reflecting a 21.5% increase from 2024, with IaaS and PaaS expected to grow by 24.8% and 21.6% respectively [1] - The rise of data privacy and security regulations, such as China's PIPL and Europe's GDPR, is significantly impacting multinational companies' data strategies, making data localization a critical issue [1] Group 2 - Pfizer's digital delivery head in China highlighted the necessity of a highly scalable, secure, and stable cloud infrastructure as a fundamental consensus for modern data strategies [2] - The challenges of cross-border data transmission and management have become a "lifeline" for companies operating in specific markets due to increasing data sovereignty awareness and regulatory developments [2] - Pfizer recognizes that data localization is not only a regulatory requirement but also essential for stable development in the Chinese market, allowing better adaptation to rapid market changes [2] Group 3 - Pfizer's core needs for data infrastructure include the necessity for global collaboration, agility to respond to market changes, and strong compliance capabilities [3] - The partnership with Amazon Web Services enables Pfizer to build a comprehensive digital ecosystem, enhancing decision-making and business operations through AI capabilities [3] - Pfizer's collaboration with Amazon in biopharmaceutical R&D has led to significant cost savings, estimated between $750 million and $1 billion annually, by leveraging data analysis and machine learning [4] Group 4 - Pfizer aims for a modern data strategy that integrates various aspects, including personnel, technology, and processes, to drive business innovation and process reengineering [4] - Continuous investment in data infrastructure and strategy, combined with AI empowerment, is expected to enhance R&D efficiency, reduce operational costs, and improve market responsiveness for pharmaceutical companies [5] - This approach is anticipated to serve as a reference for other multinational companies looking to implement data strategies in China [5]

近日， 未可知人工智能研究院副院长张孜铭在容诚会计师事务所举办的金融论坛上发表主题演讲，深入探讨了AI技术在基金行业的 创新应用与效率提升之道。 作为《DeepSeek使用指南》的作者，张孜铭从技术演进、行业实践和未来趋势三个维度，为现场观众 呈现了一场精彩纷呈的AI赋能金融盛宴。 演讲伊始，张孜铭系统梳理了AI技术的发展历程，着重分析了生成式AI与传统决策式AI的本质区别。他指出，当前以DeepSeek、 Sora为代表的生成式AI正在重塑内容生产方式，而新一代AI智能体则实现了从"回答问题"到"完成任务"的跨越式发展。 在基金行 业，这些技术已经深度渗透到投研、营销、运营等各个环节。 例如，AI文本工具可以辅助撰写专业投资报告，视频生成技术为产品 营销提供了全新可能，而智能体更是在数据处理、客户服务等方面展现出惊人的效率。 针对基金行业的具体应用，张孜铭提炼出三大提效方向：首先是信息处理的高效化，通过秘塔AI等工具可将信息搜集时间缩短80%； 其次是内容生产的自动化，利用提示词工程能快速生成营销文案和PPT；最后是业务流程的智能化，数字员工可以精准完成净值核对 等重复性工作。他特别分享了某大型基金公司的案 ...

Core Insights - Dayforce, Inc. has announced the rebranding of its payroll and HR management solution for SMEs to Powerpay by Dayforce, emphasizing a strategic shift to meet the evolving needs of over 46,000 clients across Canada [1][2][3] Company Overview - Dayforce is a global leader in human capital management technology, aiming to improve workplace life and assist thousands of clients and millions of employees worldwide [8] Industry Context - SMEs are a crucial driver of the Canadian economy, contributing billions to the GDP annually and representing nearly the entire business landscape [2] - Managing an SME has become increasingly complex due to hundreds of legislative changes each year, necessitating simple and reliable tools for compliance and payroll accuracy [2] Product Features - Powerpay is designed to simplify compliance, save time for business owners, and allow them to focus on their core operations [3] - The solution offers an intuitive user experience with enhanced features for time tracking and payroll, including a New Hire Assistant and mass self-service enrollment [4] Leadership Changes - Behrad Bayanpour has been appointed as the General Manager of Powerpay, overseeing sales, products, engineering, and services to drive the mission of providing reliable and compliant solutions for Canadian business owners [6] Client Testimonials - Clients like Apollo Property Management have praised Powerpay for transforming payroll management, highlighting its intuitive and scalable nature, which ensures accurate and timely payroll processing [5]

TORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management (HCM) leader that makes work life better, today announced the rebranding of its payroll and HR solution for Canadian small and mid-sized businesses (SMBs) as Powerpay by Dayforce, signaling a renewed strategic focus and ongoing commitment to meeting the unique and evolving needs of its more than 46,000 customers across Canada. SMBs drive Canada's economy, contributing billions to its GDP each y ...

政策动向 和黄医药宣布小分子联合疗法在中国获批 近日，和黄医药宣布，沃瑞沙（ORPATHYS，赛沃替尼/ savolitinib）和泰瑞沙（TAGRISSO，奥希替尼/ osimertinib）的联合疗法的新药上市申请获中国国家药品监督管理局（NMPA）批准，用于治疗表皮生 长因子受体（EGFR）基因突变阳性经EGFR酪氨酸激酶抑制剂（TKI）治疗后进展的伴MET扩增的局部 晚期或转移性非鳞状非小细胞肺癌患者。 资本市场 两部门发文支持创新药高质量发展 7月1日，国家医保局召开新闻发布会介绍《支持创新药高质量发展的若干措施》。其中，从加大创新药 研发支持力度、支持创新药进入基本医保药品目录和商业健康保险创新药品目录、支持创新药临床应 用、提高创新药多元支付能力、强化保障措施等5个方面提出16条具体措施，全链条支持创新药发展。 国家医保局价采中心副主任王小宁表示，中国的创新药产业已经由引进模仿转向了创新输出，为世界提 供了守卫生命健康的中国方案。2024年，中国药企完成了超过90笔海外授权的交易，总金额超过了500 亿美元。未来，国家医保局将支持更多有条件的地区发挥区位优势，搭建创新药交易平台，加强国际推 广。 ...